Risk Factors for Increased Surgical Drain Output After Transforaminal Lumbar Interbody Fusion

World Neurosurg. 2021 Jul:151:e1044-e1050. doi: 10.1016/j.wneu.2021.05.059. Epub 2021 May 24.

Abstract

Objective: To investigate the risk factors for increased surgical drain output after transforaminal lumbar interbody fusion (TLIF).

Methods: Patients who underwent TLIF in a single center from June 2017 to January 2020 were included in this study. They were divided into the increased surgical drain output group and no increased surgical drain output group according to the boundary of the median drain output. Patients' demographic and clinical parameters were compared between the 2 groups. Risk factors for increased surgical drain output were identified by univariate and multivariate logistic regression analysis.

Results: This study enrolled 368 patients who underwent TLIF. Among them, 187 patients had increased surgical drain output (drain output ≥50th percentile or 480 mL). Univariate analysis showed that age (P < 0.001), smoking status (P = 0.002), number of fused levels (P < 0.001), intraoperative blood loss (P < 0.001), intraoperative end plate injury (P < 0.001), administration of tranexamic acid (TXA) (P = 0.002), and surgical duration (P < 0.001) were significantly associated with increased surgical drain output. Multiple logistic regression analysis revealed that older age (P = 0.001), smoking (P = 0.005), more fused levels (P < 0.001), and intraoperative end plate injury (P = 0.017) were the independent risk factors, while administration of TXA (P = 0.012) was a protective factor.

Conclusions: This study showed that older age, smoking, more fused levels, and intraoperative end plate injury were the independent risk factors, while administration of TXA was a protective factor for increased surgical drain output after TLIF.

Keywords: Increased surgical drain output; Intraoperative end plate injury; Number of fused levels; Risk factors; Transforaminal lumbar interbody fusion.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antifibrinolytic Agents / therapeutic use
  • Blood Loss, Surgical*
  • Humans
  • Lumbar Vertebrae
  • Middle Aged
  • Postoperative Complications / epidemiology*
  • Retrospective Studies
  • Risk Factors
  • Spinal Fusion / adverse effects*
  • Tranexamic Acid / therapeutic use

Substances

  • Antifibrinolytic Agents
  • Tranexamic Acid